Clinical evidence summary
Durable RED YEAST RICE®
Durable
RED YEAST RICE®
Durable RED YEAST RICE was formulated by Dr. Kevin Passero based on 20 years of clinical practice—combining a standardized, full-spectrum, extra-strength dose with CoQ10 protection built in.
Every ingredient is backed by peer-reviewed human clinical trials—selected not just for scientific validation, but for results that hold up in the real world.
The Science Behind Every Ingredient
Primary Clinical Trial + 4 Independent Studies
Wang et al. 1997 · Cicero et al. · 30-RCT meta-analysis 2022
Six mechanisms confirmed across independent peer-reviewed human trials and meta-analyses—
from cholesterol and inflammation to blood sugar, blood pressure, and cardiovascular events.
A 2024 systematic review pooled results from 14 double-blind randomized controlled trials spanning 4–24 weeks, with no serious adverse events reported across any of the studies.
446 patients (primary)
5,440 patients (meta)
30 RCTs
Placebo-controlled
Double-blind
Meta-analysis
No serious adverse events
−31%
LDL cholesterol
−23%
Total cholesterol
93.2%
Therapeutic response
+17%
Endothelial function
↓ hs-CRP
Inflammation marker
−0.46 mmol/L
Fasting glucose
−3.8 mmHg
Mean arterial pressure
−0.93
Insulin resistance
Why it's included: Red yeast rice is one of the most extensively researched natural ingredients for cholesterol support—with clinical evidence spanning lipid balance, vascular function, inflammatory markers, blood sugar, and blood pressure.* The 1,600mg standardized, organic dose here is 33% higher than most comparable products, formulated to actually deliver results—with outcomes observed in as little as 8 weeks.
Citrinin-free • Extra-strength dose
Organic Red Yeast Rice
1,600
mg daily
Bioavailability Study Results
Petrangolini et al. 2019
In a 14-day crossover trial published in Current Drug Delivery (2019), 12 healthy volunteers each served
as their own control, with plasma CoQ10 levels measured against a standard 100 mg CoQ10 capsule.
A 2024 systematic review pooled results from 14 double-blind randomized controlled trials spanning 4–24 weeks, with no serious adverse events reported across any of the studies.
12 volunteers (PK)
60 adults (fatigue RCT)
0% dropout
No adverse events
Double-blind
Placebo-controlled
Crossover protocol
Up to 9×
More absorbable
+41%
Blood CoQ10 rise
48 hrs
Sustained plasma levels
Why it's included: Red yeast rice can deplete CoQ10—the nutrient your heart and muscles rely on for energy—making replenishment essential, not optional. Ubiqsome®'s Phytosome™ delivery system binds CoQ10 to sunflower lecithin for dramatically enhanced solubility, stability, and absorption—delivering 9× more than standard CoQ10 and giving your body access to the benefits most brands can't deliver.
Patented phytosome • Italian-sourced
Ubiqsome® CoQ10 Phytosome
50
mg daily
How Durable is Different
Durable's formulation is certified organic, citrinin-free, and standardized to consistent potency—so every capsule contains what the label says.
Certified organic
Citrinin-free
Standardized potency
Label-accurate
33% higher dose
A 2024 systematic review pooled results from 14 double-blind randomized controlled trials spanning 4–24 weeks, with no serious adverse events reported across any of the studies.
The Industry Problem
A 2017 NIH-cited analysis of 28 mainstream brands found none listed active ingredient quantities on the label, and levels varied more than 60-fold between products. One in three contained citrinin, a mycotoxin linked to kidney damage in animal studies.
A 2024 systematic review pooled results from 14 double-blind randomized controlled trials spanning 4–24 weeks, with no serious adverse events reported across any of the studies.
60×
Variation across
28 brands
1 in 3
Brands contained citrinin
0
Listed potency
on label
Why Purity and Standardization Matter
Clinical References
Primary Trial
Wang et al., Current Therapeutic Research 1997
Multicenter, single-masked, randomized. 446 patients with hyperlipidemia. 8 weeks. Comparator: Jiaogulan herbal medicine. Results: −30.9% LDL, −22.7% total cholesterol, +19.9% HDL, −34.1% triglycerides. 93.2% efficacy rate per China Ministry of Health criteria.
446 patients · 8 weeks · 93.2% efficacy
2022 Meta-Analysis
Systematic review · 14 double-blind RCTs · International Lipid Expert Panel
2022 systematic review and meta-analysis of 14 independent double-blind RCTs. LDL reduced −35.8 mg/dL (14–22%). Total cholesterol −37.4 mg/dL. No serious adverse events reported. Endorsed by International Lipid Expert Panel; published in Pharmacological Research.
14 RCTs · International Lipid Expert Panel
CRP & Endothelial Function
Cicero et al., University of Bologna — double-blind RCT
Double-blind, placebo-controlled, randomized. 80 hypercholesterolemic patients. 8 weeks. −23.3% LDL, −2.4% hs-CRP, +17% endothelial function (pulse volume displacement). Separate crossover trial also showed reductions in inflammatory markers including IL-6 and TNF-α in the treated group.
80 patients · double-blind · placebo-controlled
Metabolic Meta-Analysis
Frontiers in Pharmacology · 30 RCTs · 5,440 participants · 2022
Systematic review and meta-analysis of 30 RCTs. Confirmed reductions in FPG (−0.46 mmol/L), HbA1c (−0.49), HOMA-IR (−0.93), MAP (−3.8 mmHg) in metabolic syndrome populations. Cardiovascular event and mortality data represent observations within enrolled trial populations. Largest and most comprehensive RYR meta-analysis published to date.
30 RCTs · 5,440 patients · broadest evidence base
Ubiqsome® CoQ10 — Bioavailability
Fogacci et al., PMC11242215 · University of Bologna · 2024
Double-blind, randomized, placebo-controlled. 60 adults ages 65–80 on statin-based cholesterol management therapy. 8 weeks. 0% dropout, 100% compliance. −30% fatigue, +29.8% handgrip strength, +36.4% sit-to-stand improvement, +11.1% aerobic endurance vs. placebo. Results observed in this specific population; individual results may vary.
60 adults · ages 65–80 · 8 weeks · 0% dropout
Ready to Try Durable RED YEAST RICE?
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. LDL and total cholesterol results (−31%, −23%) are from Wang et al. 1997 (446 patients, 8 weeks, multicenter). Meta-analysis LDL figure (−35.8 mg/dL, 14–22%) is pooled from 14 double-blind RCTs (2022 review). CRP, endothelial function, blood glucose, insulin resistance, and blood pressure results are from the 30-RCT meta-analysis (5,440 participants, metabolic syndrome population) and University of Bologna double-blind RCTs. CoQ10 results (+116% blood levels, +36% muscle CoQ10) are from Petrangolini 2019 (PK study) and Tiano et al. (ex vivo study) respectively. Individual results may vary.
Citrinin-free • Extra-strength dose
Organic
Red Yeast Rice
1,600
mg daily
Primary Clinical Trial +
4 Independent Studies
Wang et al. 1997 · Cicero et al. · 30-RCT meta-analysis 2022
Six mechanisms confirmed across independent peer-reviewed human trials and meta-analyses— from cholesterol and inflammation to blood sugar, blood pressure, and cardiovascular events.
237 adults with elevated cholesterol took part in this 30-day randomized, double-blind,
placebo-controlled trial, conducted across two leading Italian research universities.
446 patients (primary)
5,440 patients (meta)
30 RCTs
Placebo-controlled
Double-blind
Meta-analysis
No serious adverse events
−31%
LDL cholesterol
−23%
Total cholesterol
93.2%
Therapeutic response
+17%
Endothelial function
↓ hs-CRP
Inflammation marker
−0.46 mmol/L
Fasting glucose
−3.8 mmHg
Mean arterial pressure
−0.93
Insulin resistance
Why it's included: Red yeast rice is one of the most extensively researched natural ingredients for cholesterol support—with clinical evidence spanning lipid balance, vascular function, inflammatory markers, blood sugar, and blood pressure.* The 1,600mg standardized, organic dose here is 33% higher than most comparable products, formulated to actually deliver results—with outcomes observed in as little as 8 weeks.
Patented• Italian-sourced
Ubiqsome® CoQ10 Phytosome
50
mg daily
Bioavailability
Study Results
Petrangolini et al. 2019
In a 14-day crossover trial published in Current Drug Delivery (2019), 12 healthy volunteers each served as their own control, with plasma CoQ10 levels measured against a standard 100 mg CoQ10 capsule.
237 adults with elevated cholesterol took part in this 30-day randomized, double-blind,
placebo-controlled trial, conducted across two leading Italian research universities.
12 volunteers (PK)
60 adults (fatigue RCT)
0% dropout
No adverse events
Double-blind
Placebo-controlled
Crossover protocol
Up to 9×
More absorbable
+41%
Blood CoQ10 rise
48 hrs
Sustained plasma levels
Why it's included: Red yeast rice can deplete CoQ10—the nutrient your heart and muscles rely on for energy—making replenishment essential, not optional. Ubiqsome®'s Phytosome™ delivery system binds CoQ10 to sunflower lecithin for dramatically enhanced solubility, stability, and absorption—delivering 9× more than standard CoQ10 and giving your body access to the benefits most brands can't deliver.
Why Purity and Standardization Matter
The Industry Problem
A 2017 NIH-cited analysis of 28 mainstream brands found none listed active ingredient quantities on the label, and levels varied more than 60-fold between products. One in three contained citrinin, a mycotoxin linked to kidney damage in animal studies.
60×
Variation across 28 brands
1 in 3
Brands contained citrinin
0
Listed potency on label
How Durable is Different
Durable's formulation is certified organic, citrinin-free, and standardized to consistent potency—so every capsule contains what the label says.
237 adults with elevated cholesterol took part in this 30-day randomized, double-blind,
placebo-controlled trial, conducted across two leading Italian research universities.
Certified organic
Citrinin-free
Standardized potency
Label-accurate
33% higher dose
Clinical References
Primary Trial
Wang et al., Current Therapeutic Research 1997
Multicenter, single-masked, randomized. 446 patients with hyperlipidemia. 8 weeks. Comparator: Jiaogulan herbal medicine. Results: −30.9% LDL, −22.7% total cholesterol, +19.9% HDL, −34.1% triglycerides. 93.2% efficacy rate per China Ministry of Health criteria.
446 patients · 8 weeks · 93.2% efficacy
2022 Meta-Analysis
Systematic review · 14 double-blind RCTs · International Lipid Expert Panel
2022 systematic review and meta-analysis of 14 independent double-blind RCTs. LDL reduced −35.8 mg/dL (14–22%). Total cholesterol −37.4 mg/dL. No serious adverse events reported. Endorsed by International Lipid Expert Panel; published in Pharmacological Research.
14 RCTs · International Lipid Expert Panel
CRP & Endothelial Function
Cicero et al., University of Bologna — double-blind RCT
Double-blind, placebo-controlled, randomized. 80 hypercholesterolemic patients. 8 weeks. −23.3% LDL, −2.4% hs-CRP, +17% endothelial function (pulse volume displacement). Separate crossover trial also showed reductions in inflammatory markers including IL-6 and TNF-α in the treated group.
80 patients · double-blind · placebo-controlled
Metabolic Meta-Analysis
Frontiers in Pharmacology · 30 RCTs · 5,440 participants · 2022
Systematic review and meta-analysis of 30 RCTs. Confirmed reductions in FPG (−0.46 mmol/L), HbA1c (−0.49), HOMA-IR (−0.93), MAP (−3.8 mmHg) in metabolic syndrome populations. Cardiovascular event and mortality data represent observations within enrolled trial populations. Largest and most comprehensive RYR meta-analysis published to date.
30 RCTs · 5,440 patients · broadest evidence base
Ubiqsome® CoQ10 — Bioavailability
Fogacci et al., PMC11242215 · University of Bologna · 2024
Double-blind, randomized, placebo-controlled. 60 adults ages 65–80 on statin-based cholesterol management therapy. 8 weeks. 0% dropout, 100% compliance. −30% fatigue, +29.8% handgrip strength, +36.4% sit-to-stand improvement, +11.1% aerobic endurance vs. placebo. Results observed in this specific population; individual results may vary.
60 adults · ages 65–80 · 8 weeks · 0% dropout
Ready to Try Durable
RED YEAST RICE?
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. LDL and total cholesterol results (−31%, −23%) are from Wang et al. 1997 (446 patients, 8 weeks, multicenter). Meta-analysis LDL figure (−35.8 mg/dL, 14–22%) is pooled from 14 double-blind RCTs (2022 review). CRP, endothelial function, blood glucose, insulin resistance, and blood pressure results are from the 30-RCT meta-analysis (5,440 participants, metabolic syndrome population) and University of Bologna double-blind RCTs. CoQ10 results (+116% blood levels, +36% muscle CoQ10) are from Petrangolini 2019 (PK study) and Tiano et al. (ex vivo study) respectively. Individual results may vary.